Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
26 Feb, 26
ADA 2026 outlines the standards for obesity pharmacotherapy. It recommends combining person-centered medication with lifestyle changes for adults with obesity. It details weight-loss targets and drug benefits for comorbidities
23 Feb, 26
The updated international urticaria guideline describes its definition, classification and recommendations for diagnosing and managing its various subtypes.
2 Mar, 26
Eur Urol
- This randomized study showed that biparametric MRI‑first screening, regardless of PSA levels increased biopsy (10.8% vs 5.2%) and csPCa detection (4.6% vs 1.8%) as compared to those who received bpMRI only if PSA >3 ng/ml
- Benefit–harm metrics favored MRI first, with higher grade selectivity, biopsy efficiency, and biopsy avoidance
- The strategy was cost effective with no serious adverse events.
26 Feb, 26BMC Infect Dis.
- A recent meta-analysis showed that carbapenem-resistant Klebsiella pneumoniae had significantly higher resistance to penicillins (Risk Ratios, RR 2.74), cephalosporins (ceftazidime RR 2.71, cefepime RR 2.46, cefuroxime RR 3.06), and carbapenems (imipenem RR 5.52 and meropenem RR 5.33) vs. carbapenem-susceptible Klebsiella pneumoniae
- Results highlighted the need for strict surveillance and new therapies.
26 Feb, 26Diabetes Metab Syndr...
- In 789 Indian T2DM+MASLD patients (mean age 53.3 yrs), LSM ≥9.7 in 12.9%
- FIB 4 rule in cut off: 1.68 (AUROC 0.69, sens 64.7%, spec 65.2); NFS −0.389 (AUROC 0.619, sens 61.8%, spec 57.4)
- Rule out AUROCs poor (FIB 4 0.586, NFS 0.570), conventional cut offs had low sensitivity (~21%) but high specificity (~90%)
- Overall, FIB 4/NFS poorly predicted advanced fibrosis in Indian T2DM+MASLD patients.
26 Feb, 26Hypertension.
- Phase III RCT compared low dose telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg vs telmisartan 40 mg in essential HTN patients (n=314)
- At 8 wks, combination reduced SBP more than monotherapy (LS mean diff −3.8 mmHg PPS, FAS −4.0 mmHg), DBP, normalization, & response rates favored combination
- Efficacy was consistent across clinical strata, including age & prior HTN treatment, with comparable safety profile.
2 Mar, 26
Featured
6 Mar, 26
4 Mar, 26
25 Feb, 26
